Pharmaceutical companies AbbVie Inc. and Allergan plc have agreed to divest assets to settle Federal Trade Commission charges that AbbVie’s proposed $63 billion acquisition of Allergan would violate federal antitrust law. Following an extensive investigation, the FTC alleges that the proposed acquisition would likely result in substantial competitive harm to consumers in the market for […]
Tag Archives: Manufacturing Pharmaceuticals Bureau of Competition Competition Merger
FTC Approves Final Order Imposing Conditions on Merger of Generic Drug Marketers Amneal Pharmaceuticals LLC and Impax Laboratories Inc.
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Amneal’s $1.45 billion acquisition of an equity share in Impax likely would be anticompetitive. According to the complaint, which was first announced in April 2018, the acquisition likely would harm current competition in U.S. markets for three generic […]
FTC Requires Generic Drug Marketers Amneal Pharmaceuticals LLC and Impax Laboratories Inc. to Divest Rights to 10 Generic Medications as Condition of Merger
The Federal Trade Commission will require generic drug marketers Amneal Pharmaceuticals LLC and Impax Laboratories Inc. to divest Impax’s rights and assets for 10 products to three other companies, as part of a settlement resolving charges that Amneal’s $1.45 billion acquisition of an equity share in Impax likely would be anticompetitive. Under the terms of […]
FTC Approves Final Order Preserving Competition in the U.S. Markets for Generic Drugs to Treat Certain Types of Ulcers, and Thyroid Conditions
Following a public comment period, the Federal Trade Commission has approved a final order settling charges that the $8 billion merger between Endo International plc and Par Pharmaceuticals, Inc. would likely be anticompetitive. Under the order, first announced in September 2015, the companies are required to sell Endo’s U.S. rights and assets for generic […]
FTC Requires Divestitures in Connection with Endo International plc’s Proposed Acquisition of Par Pharmaceuticals, Inc.
Pharmaceutical companies Endo International plc and Par Pharmaceuticals, Inc. have agreed to divest all of Endo’s rights and assets to generic glycopyrrolate tablets and generic methimazole tablets in order to settle Federal Trade Commission charges that Endo’s proposed $8 billion acquisition of Par likely would be anticompetitive. New Jersey-based generic drug marketer Rising Pharmaceuticals will […]
FTC Puts Conditions on Eli Lilly’s Proposed Acquisition of Novartis Animal Health
Global pharmaceutical company Eli Lilly and Company has agreed to divest its Sentinel product line of medications for treating heartworm disease in dogs in order to settle FTC charges that its proposed $5.4 billion acquisition of Novartis Animal Health would likely be anticompetitive. Under the proposed settlement, Eli Lilly will divest its Sentinel product line […]
FTC Puts Conditions on Pharmaceutical Joint Venture Between GlaxoSmithKline and Novartis
Global pharmaceutical company Novartis AG has agreed to divest Habitrol, its nicotine replacement therapy patch, to settle FTC charges that its consumer health care products joint venture with GlaxoSmithKline (GSK) would likely be anticompetitive. GSK currently sells its own nicotine replacement patch, Nicoderm CQ. London-based GSK and Switzerland-based Novartis each manufacture and market a range […]
FTC Puts Conditions on Perrigo’s Proposed Acquisition of Paddock Labs
The Federal Trade Commission will require generic drug manufacturers Perrigo Company and Paddock Laboratories, Inc. to sell six generic drugs under a proposed settlement resolving charges that Perrigo’s proposed $540 million acquisition of Paddock would be anticompetitive. The proposed settlement also contains provisions to ensure future competition in the market for generic testosterone gel products. The case […]
FTC Approves Final Order Settling Charges That Grifols, S.A.’s Acquisition of Talecris Biotherapeutics Holding Corp. Was Anticompetitive
Following a public comment period, the Federal Trade Commission approved a final order settling charges that Grifols, S.A.’s acquisition of Talecris Biotherapeutics Holdings Corp., a rival in the market for plasma-derived drugs, was anticompetitive and would have resulted in higher prices for consumers. The FTC’s order requires Grifols to sell the Talecris fractionation facility in […]
FTC Approves Final Order Settling Charges that Hikma Pharmaceuticals PLC’s Acquisition of Baxter Healthcare Assets was Anticompetitive
Following a public comment period, the Federal Trade Commission approved a final order settling charges that Hikma Pharmaceuticals PLC’s acquisition of certain Baxter Healthcare assets was anticompetitive. Specifically, the FTC complaint alleged that the transaction as proposed likely would have resulted in reduced competition and higher prices for two generic injectable drugs – phenytoin and […]